MedTrace Logo

Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer

NCT07226466 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2026-05-22

No results posted yet for this study

Summary

This study investigates the effects of brain radiotherapy on cognitive function by evaluating plasma biomarkers and apolipoprotein E (APOE) genotype in patients with primary or metastatic brain tumors. Standard brain radiotherapy is known to impact cognitive outcomes, yet the underlying biological mechanisms remain unclear.

Conditions

  • Brain Tumor Adult
  • Brain Metastases From Solid Tumors
  • Brain Tumor, Primary
  • Brain Tumor

Interventions

PROCEDURE

Blood sample

Blood sample will be collected

PROCEDURE

Brain magnetic resonance imaging (MRI)

Brain MRI will be performed during the course of data collection

PROCEDURE

Brain Health Assessment

Brain Health Assessment will be performed during the course of data collection

RADIATION

Quality of Life (QoL) Questionnaire

QoL questionnaire will be given to participants during the course of data collection

Sponsors & Collaborators

Principal Investigators

  • Jean Nakamura, MD · University of California, San Francisco

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2028-10-31
Completion
2028-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07226466 on ClinicalTrials.gov